Global ACS Market to grow at a CAGR of 13.24% over the period 2014-2019; Finds New Report

Report forecast the Global ACS market to grow at a CAGR of 13.24 percent over the period 2014-2019.

ACS is a condition that results in sudden and reduced blood flow to the heart. ACS is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and short-term mortality. On the basis of evidence of heart muscle damage and changes in the ST-tracing of the ECG, ACS is classified into three categories: STEMI, NSTEMI, and UA. ACS is treatable if it is diagnosed quickly. The treatment options for ACS vary, depending on the signs, symptoms, and overall health condition.

The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA. This report covers the present scenario and the growth prospects of the Global ACS market for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ACS.

According to the report, the elderly population, from middle-aged and older, are more prone to developing ACS because with aging, plaque accumulates in the arteries, resulting in the narrowing of the arterial passage and difficulty in blood flow to the heart.

Further, the report states that patent expiry of a drug results in the loss of the exclusive market for that particular drug, thus leading to a rapid decline in its sales. Patent expiry of a drug results in the loss of the exclusive market, resulting in a rapid decline in the sales of that particular drug.

The Global ACS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ACS market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Global ACS Market: AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc and Sanofi SA

Other Prominent Vendors in the market are: AbbVie, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck, Novartis, Pfizer, Portola Pharmaceuticals and Teva Pharmaceutical.

Key Regions

• Americas
• EMEA       
• APAC

Market Driver

• Increase in Aging Population
• For a full, detailed list, view our report

Market Challenge

• Multiple Patent Expirations
• For a full, detailed list, view our report

Market Trend

• Increase in Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 97 pages and 46 Exhibits “Global Acute Coronary Syndrome (ACS) Market 2015-2019” report covers Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Disease Overview, ACS Pipeline Landscape, Market Landscape, Market Segmentation by ECG Output, Geographical Segmentation, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis.

For further information on this report, please visit- http://mrr.cm/4xm

Find all Pharmacy Reports at: http://www.marketresearchreports.com/pharmacy